Compare Organon Pharma Indonesia Tbk. (SCPI) vs Trimegah Karya Pratama Tbk. (UVCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon Pharma Indonesia Tbk. vs Trimegah Karya Pratama Tbk. — how do they compare? Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B), while Trimegah Karya Pratama Tbk. trades at Rp155 (market cap 314.02B, 49.33M 24h volume). The key difference: Trimegah Karya Pratama Tbk. is far larger — about 3× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| SCPI | UVCR | |
|---|---|---|
Market Cap | 104.4B | 314.02B |
Volume | — | 49.33M |
Lot | — | 493.25K |
Turnover | — | 7.55B |
Average Price | — | 153.12 |
Value | — | 7.55B |
Indicative Equilibrium Price | — | 155 |
Indicative Equilibrium Volume | — | 3.77K |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →About Trimegah Karya Pratama Tbk.
PT Trimegah Karya Pratama Tbk (the Company) was established based on Notarial Deed No. 21 dated July 7, 2017 of Netty Maria Machdar, S.H. The Company started its commercial operations in 2018. The Company’s immediate parent company is PT Trimegah Sumber Mas, which was established and domiciled in Indonesia, while its ultimate Parent Company is PT Hutama Mulia Rajawali, which was established and domiciled in Indonesia.
Read more on UVCR →
